


# **AZ workflows involving D360**

William McCoull (<u>william.mccoull@astrazeneca.com</u>) Nick Tomkinson (<u>nick.tomkinson@astrazeneca.com</u>)

D360 UGM, Boston

8<sup>th</sup> October 2019



#### About us...

#### Bill McCoull

- AstraZeneca D360 business lead
- Do data analysis every day in projects
- 15+ year involvement with AZ analysis tools
- End user "I care what the tool does and how to use it"

#### Nick Tomkinson

- AstraZeneca D360 tools workstream lead
- Informatics analyst
- 20+ year involvement with AZ analysis tools
- Work with users to provide analysis & visualisation








#### Outline


1	Sample availability – switching a data category folder
2	Design workflow – calculation cache & virtual/real compounds
3	3D visualisation requirements
4	R-group stripping
5	Medchemica Matched Molecular Pairs
6	Summary





Since launch in 2015, D360 has become a key platform at AZ

# **GSM (Global Sample Management) availability**



- Previously used an ETL process to populate a static hierarchy of folders in D360 data category
  - Prone to errors lacked full reliability
- Moved to a real-time query of GSM availability
  - Kept the same folders (avoid user confusion)
  - Can add fields but not take away
  - Existing queries did not break
- Pro's
  - Improved reliability & accuracy
  - D360 query functionality allows easier & more powerful querying of availability than existing GSM tool
- Cons
  - Slow if large #cpds & complex query (not an issue for vast majority of use)



## **GSM (Global Sample Management) availability - output**

• Easy to display all samples for a specified cpd

	▼ Compound Name	⊂ CSS SName	CSS SN	CSS amt (mg)	CSS site	CSS Barcode	⊃ PLS SName	PLS SN	PLS amt (ml)	PLS concn	PLS site	PLS Barcode
1:	<u>Cpd</u> 11	Cpd 11 -004	SN1052278	17.4	Specs Netherlands	5006004946	Cpd 11 -004	SN105227 SN105227 SN105227 SN105227	0.163 0.726 0.556	10	Boston Cambridge Alderley Park	30797712 30954946 31518156


• Or aggregated data e.g. largest solid sample or largest solution sample at specified concentration/solvent available

			NLSP max (mg)	GHP CSS max (mg)	Cam CSS max (mg)	AP PLS max 10 mM (ml)	GHP PLS max 10 mM (ml)	Mo PLS max 10 mM (ml)	Cam PLS max 10 mM (ml)
1:	$\leq$	13	14.7			0.31		0.14	
2:	$\leq$	11	17.4			0.56	0.16		0.73
3:	$\leq$	5	78.1		2.8	0.08	0.05		




## **Design workflow**






- D360 facilitates the analysis step of the design-make-test-cycle
- D360 is a project query, visualisation and analysis tool







- ChemTrax used to manage progress of design sets through DMTA process
- Design sets of compounds created against design hypotheses
- Swim lanes used for each step in the process















## **3D Visualisation - Requirements**

- Dynamic selection & editing of ligand (2-way)
- Save and share visualisations
- Read target and electron density/grid information
- Access to computational methods (docking/minimisation/FEP)
- Customizable interface
- Easy ways to focus in on binding site
- High quality rendering & antialiasing, display interactions, grids & surfaces





Data View: GVK Patent Structure 15-Sep-2019 20:07 [1]

<u>File Edit Format Viewers Analysis Data Quick Search Window H</u>elp

#### 🗢 🔲 🗞 🔞 🗇 📓 🗸 🞯 📓 🐩 💯 🗒 🗉 🕤 🗃 😒 🗐 🐟 🖓 🏷 🏦 🦉 Arial 🗤 🗸 10 🗸 🕒 🛛 🖳 🖳 🖉 🗮 🐨 🖓 👘 🕞 D

Spread	readsheet  v x 3D Structure Viewer										
Spread	Inter								•	Â	
	(	GVK Id	GVK Structure	Concat Chem Connect ID	Concat AZ Number	Concat Journal Patent N	Concat Normalized Journ	Concat EntrezGene ID	Concat Official Name		load structure load pdb id
1:		124222798		407591518		WO 2019/084026 A1	WO2019084026	6921, 6923, 6923, 6923, 6923, 6923, 6923, 6923, 6923, 6923, 6923, 6923, 6923, 6923, 6923, 7428, 7428, 7428,			full structure     1901       select ligand     •       select chain     •       select residue     •
2:		124222802	ALC.	407597369		WO 2019/084026 A1	WO2019084026	6921, 6923, 6923, 6923, 7428, 7428, 7428, 8453, 8453, 8453			pocket radius clipping pocket opacity
3:		124222804		407588402		WO 2019/084026 A1	WO2019084026	6921, 6923, 6923, 6923, <b>2-way</b>	link		Cartoon backbone hydrogen sidechainAttached 189,8 N1944
4:		124222805		407589535		WO 2019/084026 A1	WO2019084026	6923, 6923, 7428, 7428, 7428, 8453, 8453, 8453		_	hydrophobic hond weak hbond bond bond bond bond bond bond bond
5:		124222806		407599052		WO 2019/084026 A1	WO2019084026	6921, 6923, 6923, 7428, 7428, 8453, 8453			<ul> <li>☑ halogen bond</li> <li>☑ metal interaction</li> <li>☑ salt bridge</li> <li>☑ cation-pi</li> <li>☑ pi-stacking</li> </ul>
6:		124222808		407597371		WO 2019/084026 A1	WO2019084026	6921, 6923, 6923, 6923, 6923, 6923, 6923, 7428, 7428, 7428, 7428, 7428, 7428, 4453, 8453, 8453,			
7.		124222810	13.20	407599051		WO 2019/084026	WO2019084026	6921, 6923, 6923, 6923, 6923, 6923, 6923, 6923, 6923, 7428,			


•\*\*

Mock-up

Data View: GVK Patent Structure 15-Sep-2019 20:07 [1]

<u>File Edit Format Viewers Analysis Data Quick Search Window H</u>elp

#### 🗢 📙 😓 💩 🗊 圖 🗸 🞯 圖 🐨 🖄 🔞 🗊 👘 😒 🌳 🌾 😚 🏥 🖘 🛠 🍫 🎼 🦠 👘 🖘



**•** 

## **R-Group Analysis**

- fRGS
- Pipeline Pilot/Spotfire
- SARPlatform
- D360
- Moesaic

Related applications

- Matched pairs
- Spark



#### D360 R-Group Analysis

Select Structures				
Use Structure Column: Stru	ucture	<b>-</b>		
Use Structures:	All 💿 Selected	I Only 💿 Marked		
Analysis Input				
Edit Core Paste 0	Core Cle	ar Core Copy Core		
-		Specify Core & R-Grou		
		Compute MCS		
	_0	Auto-assign R-Groups Core Chirality Treatme		
	F			
		Ignore		
	N	Match unspecified		
R1	R2	Exact match only		
	Analyze Structure	5		
R-Group Deconvolution Res	sults			
0 Structures Analysed				
Structures ha	ve a single core	View Structures		
Structures ha	ve multiple cores	View Structures		
Structures do	n't have core	View Structures		
Structures ha	ve errors	View Structures		
Trivial (H/LP	only) R-Groups	View		
Redefine Core				

v 9




Structure Column:	Structure		Ŧ
	Structure assigned to the FIRS	ST matching core (Hierarchical)	
Cores			
🖶 🗶 🕅 🔌	😣 🗊 💼 📝 CompoundID:		8
	Rt O	33	* * *
	Chirality Treatment		
R-Group Deconvo	Ignore Match unspecified		
R-Group Deconvo	Ignore Match unspecified		
R-Group Deconvo	Ignore Match unspecified Intion Results	ed 🔘 Exact match only	

Recent changes have removed Auto generation of MCS and R-Groups



### fRGS Workflow(s)




• Some of this functionality is available in D360 but still significant gaps



#### **Machine-Learning Atom Contributions**

Model Interpretation



Useful to see what data has contributed to the visualisation

Mats Eriksson, Hongming Chen, Lars Carlsson, J. Willem M. Nissink, John G. Cumming, and Ingemar Nilsson, Ulf Norinder, Peter Varkonyi


Journal of Chemical Information and Modeling (2014), 54(4), 1117-1128, Journal of Chemical Information and Modeling (2013), 53(6), 1324-1336



#### **Comparative performance**

		fRGS	D360	SAR Platform
1	Multiple mappings	Yes	Yes	Yes
2	Chiral R groups	Yes	Yes	Yes
3	Chirality in the core	No	Yes	Yes
4	Chirality at attachment point	No	No – scrambles core	Yes
5	Symmetry	Yes but needs improving	?	Yes
6	Double bond geometry in core	?	?	?
7	R groups as linkers	Yes except if linker is single atom	Possibly – seems odd	No – not in Auto RGroup detection.
8	R groups that cyclise onto core	Yes	Yes -but odd	No
9	"C vs N in aromatic ring"	No – need to draw 2 cores	OK for aliphatic C/O not checked for c vs n	Yes – input as SMARTS
10	Automated core perception	No	MCS removed from v10	Yes
11	#compounds matching MCS	No	No	Yes
12	Alternative tautomers in core or R groups	?	?	?
13	Double/triple bond to R groups	Yes	Yes	?






Number of bonds between linker and the 'aromatic nitrogen' pharmacophore

#### **R-Group Requirements:**

- Core entry, management and perception:
  - Autodetect core
  - Edit core or supply from scratch. Manage (save, share) cores.
- AZIDs, virtual compounds (mol/smiles), external compounds etc. from Database, SD, text and clipboard. Ideally from within D360.
- Handle poorly defined compounds chiral mixtures etc. and any enhanced features.
- Provide user-defined ability to handle equivalencing of structures, cores and R-Groups. For example, R and Racemate in R-Group.
- Also need to retain enhanced stereo in R-Group and core. (What to do about relative stereo between core and R-Group? The following example loses the relative relationship between the 2 stereo centres.) This is NOT currently handled by any approach.






### MedChemica CREATING A STEP CHANGE IN MEDICINAL CHEMISTRY

MCPairs Enterprise provides access to MedChemica's leading Artificial Intelligence and exploitation

platform. For organisations with compounds and measurements, MCPairs will extract knowledge and build a unique database of corporate knowledge. MCPairs uses the method most trusted by medicinal chemists: Matched Molecular Pair Analysis and puts it to work helping their chemists design and progress better compounds faster.

Database, API and GUI's. MCPairs can be configured to automatically update from internal databases; constantly keeping the knowledge up to date. This enables all users to instantly look up matched pairs and perform SAR analysis and free up computational chemists to concentrate on high value activities.



#### **Matched-Pairs**

"AZ have especially pair-dense data.


Prediction is 2000 CPUs for 1 month. With current 140 CPUs on HPC this will take all year (840K done so far and expected to slow down).

Running pair-finding interferes with update of existing information for current projects. (Data currently available through Ideal.)"

- Data availability through D360
- · Performance of federated teeid view unacceptable due to Union SQL statement
- ETL daily build into datamart using Pipeline Pllot




#### **Matched-Pairs: D360 Comparison viewer**





#### **Matched-Pairs: D360 formulas**





#### What next for AZ & D360?

- v19 rollout in Oct19
- HTS data integration
- More reliable curve viewer
- Integration of AI/ADD tools, 3D vis tools
- Future infrastructure



#### Summary

- Swapping/modifying data sources (GSM) requires significant planning
- D360 useful in design meetings for visualising data on real cpds
- Virtual & Real (Cpd Union) data category aids design/analysis still WIP
- 3D visualisation is important to AZ going forward
- R-group analysis and MMPA still WIP



#### **Acknowledgements**

- William McCoull
- Nick Tomkinson
- Andrew Poirrette
- Emma Evertsson
- Scott Throner
- Wolfgang Klute
- Jon Winter-Holt
- Hongming Chen
- Frank Kilty
- Kalyan Ponamalli
- Science & Enabling Units IT

#### **Confidentiality Notice**

This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK, T: +44(0)203 749 5000, www.astrazeneca.com

- Ian Ingram
- Dennis Powell
- Dave Lowis
- Certara D360 team